Väsby Läkargrupp has been acquired by Doktor.se
The shareholders of Väsby Läkargrupp have sold the company to Doktor.se.
Väsby Läkargrupp is a healthcare provider offering primary care, occupational health care and vaccinations through a clinic located in Upplands Väsby in Sweden. The company was founded in 1987 and has approximately 45 employees.
Doktor.se is a digital healthcare and technology company offering digital triage and treatment through its digital healthcare platform as well as through physical clinics in Sweden. The company was founded in 2016 and is one of Sweden’s leading digital healthcare providers.
Oaklins’ team in Sweden acted as financial advisor to the sellers in this transaction.
Talk to the deal team
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn moreBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Learn more